Syndetics cover image
Image from Syndetics

Bottle of lies : the inside story of the generic drug boom / Katherine Eban.

By: Material type: TextTextPublisher: New York, NY : Ecco, an imprint of HarperCollins Publishers, [2019]Copyright date: ©2019Edition: First editionDescription: xxiv, 482 pages ; 24 cmContent type:
  • text
Media type:
  • unmediated
Carrier type:
  • volume
ISBN:
  • 9780062338785
  • 0062338781
  • 9780062338792
  • 006233879X
Subject(s):
Contents:
Part I: Shifting ground. The man who saw further ; The gold rush ; A slum for the rich ; The language of quality ; Red flags -- Part II: India rises. Freedom fighters ; One dollar a day ; A clever way of doing things ; The assignment -- Part III: A cat-and-mouse business. The global cover-up ; Map of the world ; The pharaoh of pharma -- Part IV: Making a case. Out of the shadows ; "Do not give to FDA" ; "How big is the problem?" ; Diamond and ruby ; "You just don't get it" -- Part V: Detectives in the dark. Congress wakes up ; Solving for X ; A test of endurance ; A deep, dark well ; The $600 million jacket -- Part VI: The watershed. The light switch ; We are the champions ; Crashing files ; The ultimate testing laboratory -- Part VII: Reckonings. Flies too numerous to count ; Standing.
Summary: "Many have hailed the widespread use of generic drugs as one of the most important public-health developments of the twenty-first century. Today, almost 90 percent of our pharmaceutical market is comprised of generics, the majority of which are manufactured overseas. We have been reassured by our doctors, our pharmacists and our regulators that generic drugs are identical to their brand-name counterparts, just less expensive. But is this really true? Katherine Eban's Bottle of Lies exposes the deceit behind generic-drug manufacturing--and the attendant risks for global health. Drawing on exclusive accounts from whistleblowers and regulators, as well as thousands of pages of confidential FDA documents, Eban reveals an industry where fraud is rampant, companies routinely falsify data, and executives circumvent almost every principle of safe manufacturing to minimize cost and maximize profit, confident in their ability to fool inspectors. Meanwhile, patients unwittingly consume medicine with unpredictable and dangerous effects. The story of generic drugs is truly global. It connects middle America to China, India, sub-Saharan Africa and Brazil, and represents the ultimate litmus test of globalization: what are the risks of moving drug manufacturing offshore, and are they worth the savings?" -- Dust jacket.
Holdings
Item type Home library Collection Call number Materials specified Status Date due Barcode Item holds
Adult Book Adult Book Dr. James Carlson Library NonFiction 615.1 E15 Available 33111009357670
Adult Book Adult Book Main Library NonFiction 615.1 E15 Available 33111009160611
Total holds: 0

Enhanced descriptions from Syndetics:

A NEW YORK TIMES BESTSELLER * New York Times Notable Book * Best Book of the Year: New York Public Library, Kirkus Reviews, Science Friday

With a new postscript by the author

From an award-winning journalist, an explosive narrative investigation of the generic drug boom that reveals fraud and life-threatening dangers on a global scale--The Jungle for pharmaceuticals

Many have hailed the widespread use of generic drugs as one of the most important public-health developments of the twenty-first century. Today, almost 90 percent of our pharmaceutical market is comprised of generics, the majority of which are manufactured overseas. We have been reassured by our doctors, our pharmacists and our regulators that generic drugs are identical to their brand-name counterparts, just less expensive. But is this really true?

Katherine Eban's Bottle of Lies exposes the deceit behind generic-drug manufacturing--and the attendant risks for global health. Drawing on exclusive accounts from whistleblowers and regulators, as well as thousands of pages of confidential FDA documents, Eban reveals an industry where fraud is rampant, companies routinely falsify data, and executives circumvent almost every principle of safe manufacturing to minimize cost and maximize profit, confident in their ability to fool inspectors. Meanwhile, patients unwittingly consume medicine with unpredictable and dangerous effects.

The story of generic drugs is truly global. It connects middle America to China, India, sub-Saharan Africa and Brazil, and represents the ultimate litmus test of globalization: what are the risks of moving drug manufacturing offshore, and are they worth the savings?

A decade-long investigation with international sweep, high-stakes brinkmanship and big money at its core, Bottle of Lies reveals how the world's greatest public-health innovation has become one of its most astonishing swindles.

Includes bibliographical references (pages [421]-461) and index.

"Many have hailed the widespread use of generic drugs as one of the most important public-health developments of the twenty-first century. Today, almost 90 percent of our pharmaceutical market is comprised of generics, the majority of which are manufactured overseas. We have been reassured by our doctors, our pharmacists and our regulators that generic drugs are identical to their brand-name counterparts, just less expensive. But is this really true? Katherine Eban's Bottle of Lies exposes the deceit behind generic-drug manufacturing--and the attendant risks for global health. Drawing on exclusive accounts from whistleblowers and regulators, as well as thousands of pages of confidential FDA documents, Eban reveals an industry where fraud is rampant, companies routinely falsify data, and executives circumvent almost every principle of safe manufacturing to minimize cost and maximize profit, confident in their ability to fool inspectors. Meanwhile, patients unwittingly consume medicine with unpredictable and dangerous effects. The story of generic drugs is truly global. It connects middle America to China, India, sub-Saharan Africa and Brazil, and represents the ultimate litmus test of globalization: what are the risks of moving drug manufacturing offshore, and are they worth the savings?" -- Dust jacket.

Part I: Shifting ground. The man who saw further ; The gold rush ; A slum for the rich ; The language of quality ; Red flags -- Part II: India rises. Freedom fighters ; One dollar a day ; A clever way of doing things ; The assignment -- Part III: A cat-and-mouse business. The global cover-up ; Map of the world ; The pharaoh of pharma -- Part IV: Making a case. Out of the shadows ; "Do not give to FDA" ; "How big is the problem?" ; Diamond and ruby ; "You just don't get it" -- Part V: Detectives in the dark. Congress wakes up ; Solving for X ; A test of endurance ; A deep, dark well ; The $600 million jacket -- Part VI: The watershed. The light switch ; We are the champions ; Crashing files ; The ultimate testing laboratory -- Part VII: Reckonings. Flies too numerous to count ; Standing.

Powered by Koha